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In the past decade, an increasing frequency of acute hepatitis E was noted in Germany
and other European countries. Moreover, a high prevalence (17%) of hepatitis E virus
(HEV) immunoglobulin G antibodies (anti-HEV) was recently found in the adult Ger-
man population. Although this suggests an emerging pathogen, reports from other
countries gave hints to a completely new aspect: a possible decrease in anti-HEV preva-
lence during the last decades. To investigate the time trends of hepatitis E in southeast-
ern Germany, we performed anti-HEV testing in sera taken from adults in 1996 and
2011. Surplus serum specimens stored during routine operations of our diagnostic labo-
ratory were used. The sample comprised two sets of 1,092 sera taken in 1996 and 2011,
each with 182 specimens in six age groups from 20-79 years. Testing was performed
using an HEV IgG enzyme immunoassay (EIA, Axiom Diagnostics), and the recomLine
HEV IgG immunoblot (Mikrogen). A significant difference in anti-HEV prevalence was
observed between the two groups: 50.7% of individuals tested positive in the 1996
group as compared to 34.3% in 2011 (EIA, P< 0.001). Results by immunoblot analysis
were 20.5% (1996) versus 14.5% (2011), P< 0.001. Differences were found in all age
groups and were more pronounced for the 20-39-year age group. Conclusion: The preva-
lence of anti-HEV has decreased significantly in the past decades in southeastern Ger-
many. The phenomenon of HEV being an emerging pathogen is thus most probably
due to an increasing awareness of the disease. (HEPATOLOGY 2014;60:1180-1186)
H
epatitis E virus (HEV) is a small, nonenvel-
oped RNA virus with a genome size of 7.2
kb. HEV is a member of the genus Hepevirus,
family Hepeviridae. The virus was first postulated in
1980 as a causative agent of enterically transmitted
non-A, non-B hepatitis in India and was identified 3
years later.1 Subsequent analyses of viral genomes led
to the identification of four mammalian HEV geno-
types with distinct geographic distributions. Genotype
1 is a major cause of infectious hepatitis transmitted
by the fecal-oral route in Asia and Africa.2 Conse-
quently, acute hepatitis E has previously been consid-
ered an exclusively travel-associated disease acquired in
one of these geographic areas. However, evidence has
accumulated that HEV infection also occurs among
individuals in industrialized countries with no history
of travel to HEV-endemic areas.3-5 These autochtho-
nous cases are caused mainly by HEV genotype 3 (and
in rare instances genotype 4) strains.3,5-8 Because geno-
type 3 isolates from human cases were almost identical
to strains detected in swine and wild boars, zoonotic
sources of infection are suspected.7,9,10 HEV genotype
3 infections are usually asymptomatic and hence
remain undiagnosed. Only a very small minority of
cases, probably less than 1%,11 show symptoms of
acute viral hepatitis. However, several chronic cases
have been reported in transplant recipients.12-14
In Germany, as in other European countries,15,16 a
rapidly increasing frequency of acute hepatitis E has
been noted in the past decade, with 32 notified cases
in 200317 rising to 454 cases in 2013.18 The majority
of strains isolated from patients with acute hepatitis E
in Germany were genotype 3.5,7,19 Despite relatively
low numbers of acute cases, surprisingly high anti-
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HEV prevalence estimates were reported in different
European populations.20,21 In contrast to other studies,
which reported lower rates, these studies applied anti-
HEV detection assays with higher sensitivity for the
prevalent genotype 3 strains.
The anti-HEV prevalence was recently determined
in a large representative sample of the German adult
population. The overall prevalence as determined by
immunoblot was 16.8%, increased with age, and lev-
eled off at >60 years of age.11 In summary, these char-
acteristics all imply that HEV is an emerging
pathogen. In sharp contrast to this notion, two recent
reports from England and Denmark gave hints of a
completely new aspect: a possible decrease in anti-
HEV prevalence during the past decades.22,23 Refer-
ring to these publications, the purpose of our work
was to investigate these hints in more detail by con-
ducting a study which is 1) appropriately powered, 2)
geographically focused, and 3) based on comparable
study participants. The principal question was whether
there is a significant time trend of hepatitis E seropre-
valence in Southeastern Germany. To answer this ques-
tion, sera taken from adults in 1996 and 2011 were
analyzed for the presence of anti-HEV.
Materials and Methods
Sample Composition and Study Design. A total
of 2,184 specimens were included in the study. In all,
1,092 (50%) samples were collected in 1996 and
1,092 were collected in 2011. In the 1996 sample set,
96.3% (1,052/1,092) were from the federal state of
Bavaria in southeastern Germany. A minority of 3.7%
(40/1,092) were from other German federal states or
could not be assigned to a distinct geographic location.
The corresponding numbers for the 2011 sample set
are 96.4% (1,053/1,092) and 3.6% (39/1,092), respec-
tively. The specimen sets comprised six age groups for
1996 and 2011, respectively, each consisting of 182
samples. An equal gender distribution was chosen
within each of the 12 age groups (Fig. 1).
Sample Collection. All serum samples were
obtained as part of the daily routine operations of our
diagnostic laboratory in 1996 and 2011, and only
stored surplus serum was used for this study. Samples
were randomly chosen from all available specimens of
a certain age group with no preselection as to the
patients’ clinical characteristics. If a specimen was
included in the 1996 sample set, specimens available
from the same person in 2011 were excluded. All sera
were stored at 220C prior to testing.
Reference Reagents. The WHO reference reagent
(NIBSC code: 95/584) for antibodies to HEV was
used as a biological standard for antibody concentra-
tion.24 Moreover, a second reference reagent contain-
ing antibodies against HEV genotype 3 was analyzed.7
Details about the reference reagents and experimental
setup are presented in the Supporting Information.
Laboratory Analysis. Serum samples were tested
for the presence of anti-HEV using two commercially
available immunoassays: the Axiom Diagnostics
(Worms, Germany) HEV IgG EIA (developed by
Wantai, Beijing, China), and the Mikrogen recomLine
HEV IgG immunoblot (Mikrogen, Neuried, Ger-
many), denoted hereafter as EIA and immunoblot,
respectively. A cutoff optical density (OD) for the EIA
was determined according to the manufacturer by add-
ing 0.16 to the arithmetic mean of the negative con-
trol ODs. For each measurement, a signal-to-cutoff
ratio (SCR) was calculated by dividing the respective
OD by the cutoff OD. A modified EIA scoring system
was applied with a negative result being recorded for
SCRs of 1.1, and a positive result for SCRs of >1.1.
The quantitative interpretation of SCR values was pos-
sible within the linear range of the assay (Supporting
Information Fig. 1). The immunoblot is based on
seven recombinant antigens of HEV genotypes 1 and
3. Stained test strips were scanned with the semiauto-
mated recomScan apparatus and results were calculated
with the respective analysis software (Mikrogen). Each
antigen band with an intensity greater than or equal to
the cutoff band was assigned a predefined point value.
The final results were classified into two categories:
negative (defined as 2 points) and positive (defined
as 3 points). To achieve better comparability of the
analytical performance experiments, SCR values were
also calculated for immunoblot measurements by
dividing the mean ODs of reactive antigen bands by
the density of the respective cutoff band.
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Statistical Analysis. To determine a suitable sam-
ple size, the assumption was made that the anti-HEV
prevalence in 1996 differed by at least 5% from the
prevalence in 2011. We estimated that 1,092 subjects
were necessary per sample year to detect a significant
effect with 95% confidence and 85% statistical power.
Sample size and power calculations were performed
with the software G*Power 3.25 Random sampling of
specimens was carried out with the sample() function
implemented by the R programming language (R
Foundation for Statistical Computing). Pearson’s v2
test was used to evaluate differences between the anti-
HEV prevalence rates in 1996 and 2011. Data proc-
essing and statistical analysis were performed with
SPSS v. 20.0 (IBM, Ehingen, Germany). A statistically
significant difference was defined as P< 0.05.
Results
Anti-HEV Prevalence in 1996 and 2011. In both
assays, a significantly higher anti-HEV prevalence was
seen in the group sampled in 1996 than in the indi-
viduals from 2011. By EIA, 50.7% (554/1,092) were
positive for anti-HEV in 1996 and 34.3% (375/1,092)
were positive in 2011 (P< 0.001). The corresponding
values obtained by the immunoblot assay were 20.5%
(224/1,092) and 14.5% (158/1,092; P< 0.001) (Fig.
2A). Although the results by the two methods differed
considerably, in both groups sera tested positive by
immunoblot were an almost complete subset of the
positive sera by EIA (Fig. 2B): 96.4% and 94.9%,
respectively, of immunoblot-positive sera tested in
1996 and 2011 were also positive with EIA, whereas
only a small percentage of 3.6% and 5.1% were solely
immunoblot-positive.
Analysis of Different Age Groups. Anti-HEV
prevalence increased with age between 20 and 59 years
in the 1996 group and between 30 and 69 years in
the 2011 group (Fig. 3). Gender-specific differences
were not observed (data not shown). Comparison of
the EIA prevalence estimates by age group between
1996 and 2011 showed significantly lower rates in
2011 for the age groups 20-29 years (P5 0.001), 30-
39 years (P< 0.001), 40-49 years (P< 0.001), and 50-
59 years (P5 0.002). Differences were not significant
in the age groups 60-69 years (P5 0.345) and 70-79
years (P5 0.173; Fig. 3A). Results obtained with the
immunoblot assay were almost identical to the EIA
results but on a considerably lower level. Accordingly,
significant differences were found in the age groups of
20-49 years: 20-29 years (P5 0.022), 30-39 years
(P< 0.001), 40-49 years (P5 0.031), 50-59 years
(P5 0.307), 60-69 years (P5 0.218), and 70-79 years
(P5 0.197; Fig. 3B). The anti-HEV prevalence in the
two 60-69 year age groups as assessed by immunoblot
showed—different from all other comparisons—a
lower value in 1996 (P5 0.218). The 60-69 year age
group also showed a lower value in the EIA assay than
the older and younger age groups, causing a dip in the
curve of the prevalence values (Fig. 3A). The most
pronounced absolute difference in the prevalence rates
between 1996 and 2011 was found in the age group
Fig. 1. Study design and sample composition. HEV, hepatitis E virus; IgG, immunoglobulin G; EIA, enzyme immunoassay.
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30-39 years: a 36.3% lower value when measured by
EIA (P< 0.001) and a 14.9% lower value when meas-
ured by immunoblot (P< 0.001). The difference
decreased continuously between 30 and 59 years.
Comparing the EIA profiles of 30 acute hepatitis E
cases7 with anti-HEV positive samples from an exem-
plary age-group in the current study showed that acute
or recent cases show a single high peak of anti-HEV
reactivity, whereas the groups analyzed in the current
study show a broader distribution of anti-HEV SCRs
(Supporting Information Fig. 2A,B).
Birth Cohort Analysis. Anti-HEV prevalences of
the 1996 and 2011 groups were also analyzed accord-
ing to the birth cohort. Both groups included individ-
uals born between 1930 and 1979. Surprisingly, in all
10-year birth cohorts, individuals sampled in 2011
showed lower anti-HEV prevalences than those
sampled in 1996 (Fig. 4, Supporting Information
Table). Whereas these differences were only marginal
in the two youngest groups (born 1960-1969 and
1970-1979), they became rather evident in individuals
born between 1930 and 1959, reaching statistical sig-
nificance in the 1940-1949 birth cohort (P5 0.02),
suggesting a loss of specific antibodies over time. Ana-
lyzing the distribution of SCR values by EIA allowed
us to approximate the proportion of acute or recent
infections empirically, defined as samples with SCR
16: all birth cohorts had a lower rate of acute or
recent infections in 2011 as compared to 1996 (Sup-
porting Information Fig. 2C).
Analytical Performance Validation of the Immu-
noassays. The analytical performance of the anti-
HEV detection assays was evaluated by analyzing a
Fig. 3. Anti-HEV prevalence shown by age group. (A) Results
obtained by EIA. (B) Results obtained by immunoblot analysis.
Fig. 2. (A) Anti-HEV prevalence in 1996 and 2011. Results were
generated with the Axiom Diagnostics HEV IgG enzyme immunoassay
(EIA), and the Mikrogen recomLine HEV IgG assay (immunoblot). Pear-
son’s v2 test was used to evaluate differences between the anti-HEV
prevalences in 1996 and 2011. (B) Schematic distribution of results
generated with the EIA and with the immunoblot. Absolute numbers
and calculated ratios (%) are indicated. Pos., positive; neg., negative.
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dilution series of the two reference reagents. In sum-
mary, both assays proved to be capable of sensitively
detecting anti-HEV in dilutions of both reference
materials. The lower limit of detection (LoD, defined
as the lowest anti-HEV concentration with a positive
test result) for the World Health Organization
(WHO) reagent was determined at 0.39 U/mL with
the EIA and 0.78 U/mL with the immunoblot
assay. The corresponding values for the genotype 3 ref-
erence were 0.39 U/mL (EIA) and 1.57 U/mL (immu-
noblot). Detailed results of the analytical performance
validation are presented in Supporting Information
Fig. 1.
Discussion
In this study we examined whether the prevalence
of anti-HEV has changed over time in southeastern
Germany. To address this issue, we compared sera
taken from adults in 1996 and 2011 using two
different anti-HEV detection assays. Our results show
that 1) overall anti-HEV prevalence has declined sig-
nificantly over time; 2) the decrease in prevalence is
most prominent in the 20-49 year age group; and 3)
this effect is evident regardless of the detection assay
used.
Our findings are substantiated by an assay perform-
ance validation, which shows that both assays are suita-
ble for detecting anti-HEV directed against the
relevant HEV genotypes. The study was designed to
detect a 5% difference in anti-HEV prevalence with
85% statistical power and a 5% probability of error.
Statistical analysis demonstrated an overall decline in
anti-HEV prevalence of 15.7% (EIA) and 6% (immu-
noblot) with P< 0.001. This finding is supported by
the fact that significant decreases in anti-HEV preva-
lence were also found in the analyses for the younger
age groups and with data generated by both detection
assays. However, no statistically significant difference
was found in the 60-69 and 70-79 year age groups.
Surprisingly, birth cohort analysis showed in all
groups higher prevalences in sera taken in 1996 versus
sera of 2011. Differences were marginal in those born
in 1970-79 and 1960-69, but higher in the other
groups and even statistically significant in the 1940-
1949 birth cohort. A likely interpretation is the occur-
rence of waning immunity, manifesting itself as a
decreasing anti-HEV concentration after infection over
time.26 Thus, the observed difference in the total anti-
HEV prevalence would be the result of negative sero-
conversions due to waning immunity, considerably
outnumbering positive seroconversions due to novel
HEV infections (and probably reinfections) at the
same time.26,27 This interpretation is supported by the
SCR distribution analysis, where acute cases7 show a
single high peak of anti-HEV reactivity, whereas the
groups analyzed in the present study showed a broader
SCR distribution. A limitation of our study is that fur-
ther investigation of this aspect is not possible due to
the lack of consecutively drawn serum samples. Mathe-
matical models aimed at estimating the incidence and
force of infection (FOI) regularly assume constant
seropositivity after infection.11 Since we cannot sepa-
rately characterize the extent of positive versus negative
seroconversions, we did not apply mathematical mod-
eling. Nevertheless, the high prevalence in subjects
born before 1960 implies that these individuals lived
through a period with increased risk of HEV transmis-
sion, but this risk has been decreasing since and is cur-
rently at a lower level. The lower ratio of putative
acute or recent infections observed in the 2011 sample
supports this conclusion.
Previous studies have found high anti-HEV preva-
lences in Germany and other industrialized countries,
which were previously regarded as nonendemic for
HEV.11,19,20 The anti-HEV prevalence for our 2011
sample fits well with these previous reports.11,19 It is a
limitation of our study that we could only test left-
over sera of a confined geographic origin. However, a
nationwide study found no differences between anti-
HEV prevalence rates in different geographical areas
within Germany.11 Although these data do not com-
pletely rule out risk variations in certain age groups or
localizations (e.g., in the older population due to the
Fig. 4. Anti-HEV prevalence shown by birth cohort. Results were
obtained by EIA.
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former separation of the country), it is yet tempting to
speculate that our results are representative for all of
Germany.
Recently, evidence has accumulated that different
anti-HEV detection assays strongly affect anti-HEV
prevalence estimates.19,21 Hence, it is a technical pre-
requisite that assays with high sensitivity for HEV
genotype 3 are used for prevalence studies in Europe.
We demonstrated in this work that both detection
assays used fulfill these requirements. Moreover, the
comparability of results to other studies is warranted
by using the same immunoblot assay as previously.11,19
The distribution of results shows that the positives by
immunoblot are almost a complete subset of the posi-
tives by EIA. This can be explained by the higher sen-
sitivity of the EIA. Random results due to a lack of
specificity would not show such a pattern.19
Two previous studies monitored anti-HEV prevalence
over time. Unexpectedly, both studies found hints of
effectively declining anti-HEV prevalences. However,
both studies were limited for several reasons. Ijaz et al.
determined the anti-HEV prevalence in 2,731 samples
from England and Wales.22 The authors used a sensitive
HEV IgG EIA, but—different from our results—found
no significantly different anti-HEV prevalences in the
1991 (13.0%) and 2004 (13.5%) sample collections.
Cautious interpretation of these results is necessary
because the geographical origin of the samples was from
two whole countries. Also, samples were unevenly
matched between the two sampling years. A sampling
effect might thus have influenced the overall result or
regional differences might have been overlooked. Ijaz
et al.22 found an overall association between increase in
prevalence and increase in age. The authors speculate that
the risk of acquiring HEV infection in England and Wales
rose sharply during the mid-20th century, but then
decreased at the end of the 1950s and currently remains
low. Our results from the birth cohort analysis fit well
with this model. The second study by Christensen et al.
compared the anti-HEV prevalence in Denmark by ana-
lyzing two sets of sera taken in 1983 (n5 169) and 2003
(n5 461).23 The authors found a significant decrease in
anti-HEV prevalence from 32.9% to 20.6%. However,
cautious interpretation is advisable due to the small sam-
ple size, uneven sample distribution (according to sample
years), and the divergent sample origin (blood donors,
farmers, and prisoners). In order to avoid these potential
drawbacks, our study comprised a significantly larger sam-
ple size and was based on two geographically focused and
highly comparable study collectives. Our results suggest
that the rate of HEV exposure has decreased considerably
in the past. This notion is supported by a study on the
evolutionary history and population dynamics of HEV:
based on in silico modeling, the authors propose that
genotypes 3 and 4 have experienced an increase in popu-
lation size in the first half of the 20th century, followed by
a decline of unknown cause around 1990.28 Another
study from Japan points in the same direction. However,
the latter model anticipates an increase in HEV genotype
3 population size in Japan around 1960-1970, followed
by a decline around 2000.29
Some important questions remain: why is a large
portion of the German population anti-HEV positive?
What is the reason for the declining prevalence in the
last decades? There is now a growing body of evidence
suggesting that autochthonous HEV infections are
transmitted by ingestion of contaminated pork prod-
ucts.7,30-34 If this is the major mode of transmission,
then there must also have been a significant reduction
in alimentary exposure to HEV in the past decades,
presumably resulting in the interruption of HEV trans-
missions. We can only speculate that improvements in
the food industry are the underlying reason, since the
per capita pork intake was relatively stable between
1990 and 2010 in Germany.
In summary, our study shows that the anti-HEV
prevalence has significantly decreased in the past deca-
des in southeastern Germany. The risk of HEV infec-
tion was likely higher in the first half of the 20th
century and has been decreasing in the past decades.
Currently observed increasing numbers of acute hepati-
tis E cases should be therefore interpreted as an artifact
probably caused by a higher awareness of the disease.
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